Sandwich, UK — 25 March 2026: Discovery Park, Kent’s science and innovation hub, has launched the sixth edition of its Discovery Spark accelerator programme, welcoming 11 startups to its campus in Sandwich.
Amsbio announce the RPMotion – a spinning organoid bioreactor that facilitates fast, easy and efficient organoid culture for drug discovery, disease modelling and regenerative medicine.
LONDON, UK, March 18, 2026 / Biotech Newswire / -- Touchlight, in collaboration with New England Biolabs (NEB®), announces the launch of the EnClose™ Cell-free dbDNA™ Synthesis Kit, a new benchtop solution enabling rapid enzymatic production of Touchlight’s proprietary doggybone DNA™ (dbDNA™).
About Sygnature Discovery
At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible.
We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.
Your role
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
The Company
Senior figures from across industry, academia, investment and government met yesterday (Thursday 26 March 2026) at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood, to discuss the findings of a new report commissioned by Pioneer Group and The Crown Estate, and authored by Henham Strategy.
Join us at Hauxton House for the o2h ChaiTime — Discovery Club.
We are excited to introduce o2h ChaiTime — Discovery Club - an invite-only forum designed to bring together Medicinal Chemists and Drug Discovery leaders for an open, peer-led discussion on emerging therapeutic areas and modalities.
Featuring the Cambridge Chemistry Club, we are bringing together a curated group of biotech leaders and decision-makers to present and discuss emerging modalities, evolving drug discovery strategies, and real-world insights across diverse therapeutic areas.
• Cutting-edge platform technology leveraging advanced molecular dynamics to uncover protein metastates and reveal novel binding sites in difficult to target proteins.
• Combining RxPlorer™ with our in vitro capabilities, RxCelerate can deliver rapid hit identification and screening in 2 months.
Cambridge, UK and Cambridge, MA – 24/3/26 1pm GMT